Global Veterinary Dermatology Drugs Market Size to worth USD 39.86 Billion by 2033: Market Insight Report

RELEASE DATE: Apr 2025 Author: Spherical Insights
The Global Veterinary Dermatology Drugs Market Size is Expected to Grow from USD 15.8 Billion in 2023 to USD 39.86 Billion by 2033, at a CAGR of 9.70% during the forecast period 2023-2033.

Table of Contents

Historical Data, Premium Insights, Market Dynamic, Analysis and Projection, By Product, Analysis and Projection, By Application, Analysis and Projection, By End-Use, Analysis and Projection, By Regional Analysis, Competitive Landscape, Company Profiles, Market Revenue, Sale & Price Analysis


Related Topics

Veterinary Furniture Market Size IoT Insurance Market Size POS Security Market Size Crop Reinsurance Market Size

Global Veterinary Dermatology Drugs Market Size to worth USD 39.86 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Veterinary Dermatology Drugs Market Size is Expected to Grow from USD 15.8 Billion in 2023 to USD 39.86 Billion by 2033, at a CAGR of 9.70% during the forecast period 2023-2033. 

 

Browse key industry insights spread across 210 pages with 110 Market data tables and figures & charts from the report on the Global Veterinary Dermatology Drugs Market Size, Share, and COVID-19 Impact Analysis, By Indication (Parasitic Infections, Allergic Infections, and Others), By Type (Prescription and OTC), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.   

       

The veterinary dermatology drugs market includes the development, manufacturing, and distribution of pharmaceutical products designed for the treatment of various skin conditions and diseases among animals. It is used for the treatment of dermatitis, parasitic infections, fungal infections, and other allergic skin responses in companion and livestock animals. The market reaches veterinary clinics and hospitals, as well as retail pharmacies, offering an assortment of drugs, including topical creams, oral medications, and injectables. The market is currently expanding due to the increasing prevalence in animal skin conditions, awareness concerning the health of pets, and progress in dermatological treatments in veterinarians. Along with the surge in the pet-keeping population and the humanization of pets, the demand for adequate dermatology medications is on an all-time rise for companion animals. Innovations in drug formulations and the incorporation of new types of therapy into the market like monoclonal antibodies are supporting growth in this market. However, factors such as the high cost of advanced dermatology treatments, limited access to veterinary care in some regions, and the potential for adverse drug reactions may restrain market growth.

 

The parasitic infections segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period.

Based on the indication, the veterinary dermatology drugs market is classified into parasitic infections, allergic infections, and others. Among these, the parasitic infections segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period. The dominance of this segment can be attributed to the high prevalence of parasitic skin conditions in animals, including mange, flea infestations, and tick-borne dermatitis. Parasitic infections are among the most common dermatological issues encountered in veterinary practices, particularly in companion animals such as dogs and cats, as well as livestock.

 

The prescription segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period.    

Based on the type, the veterinary dermatology drugs market is divided into prescription and OTC. Among these, the prescription segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period. The dominance of this segment is primarily due to the prevalence of severe and chronic dermatological conditions in animals that require specialized and veterinarian-prescribed treatments. Conditions such as allergic dermatitis, fungal infections, and complex parasitic infestations often necessitate prescription drugs for effective management.

 

North America is estimated to hold the largest veterinary dermatology drugs market share over the forecast period.

North America is estimated to hold the largest veterinary dermatology drugs market share over the forecast period. These can be attributed to the presence of key companies, high expenditure on pets, pet humanization, and rising awareness about animal disease. For example, market leaders like Zoetis; Merck & Co., Inc.; and Elanco Animal Health, are headquartered in the U.S. and undertake various strategic initiatives to increase their market share. Regulatory agencies like the FDA continue to approve new treatments, which open up more choices for veterinarians and pet owners.

 

Asia-Pacific is predicted to have the fastest CAGR growth in the veterinary dermatology drugs market over the forecast period. With economies in the Asia Pacific region continuing to grow, there is a noticeable increase in the size of the middle-class population, higher disposable incomes, and growing urbanization. Market players have begun to capture opportunities in these emerging markets. China, in particular, shows strong momentum due to advancements in veterinary pharmaceuticals and government support for pet healthcare. For example, in October 2024, FelicaMed Biotechnology received approval from China's Ministry of Agriculture and Rural Affairs for Lirucitinib, a Class I veterinary drug for the treatment of canine pruritus.

 

Company Profiling

Major key players in the veterinary dermatology drugs market are Elanco, Ceva, Vetoquinol, Merck & Co., Inc., Zoetis, Virbac, Bimeda, Inc, Vivaldis, Bioiberica S.A.U., Boehringer Ingelheim International GmbH, and  Others.

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Development

  • In September 2024, Elanco launched Zenrelia (ilunocitinib tablets), a once-daily oral JAK inhibitor for the management of allergic and atopic dermatitis in dogs 12 months of age and older. Zenrelia offers significant itch relief and affordability, making it a safer, more effective alternative to competitors.

 

Market Segment

This study forecasts global, regional, and country revenue from 2023 to 2033. Spherical Insights has segmented the veterinary dermatology drugs market based on the below-mentioned segments:

 

Global Veterinary Dermatology Drugs Market, By Indication

  • Parasitic Infections
  • Allergic Infections
  • Others

 

Global Veterinary Dermatology Drugs Market, By Type

  • Prescription
  • OTC

 

Global Veterinary Dermatology Drugs Market, By Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Recent Insights


Your personal details are safe with us, Privacy Policy.

Thank You!

We have received your message and would like to thank you for writing to us. If your inquiry is urgent, please use the telephone number listed below to talk to one of our staff members. Otherwise, we will reply by email as soon as possible.

+1 303 800 4326 +91 9561448932 emailsales@sphericalinsights.com

We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies